Zydus Lifesciences experienced a marginal decline in the early trade on January 18 after securing approval from the United States Food and Drug Administration (USFDA) for a generic antipsychotic drug. At 9:24 am, the company’s shares were quoting at Rs 708.80, down Rs 0.90, or 0.13 percent, on the NSE.
The pharmaceutical company announced that it had received final approvals from the USFDA to manufacture and market Pimavanserin Capsules, 34 mg, and Pimavanserin Tablets, 10 mg. Pimavanserin is categorized as an atypical antipsychotic used for treating hallucinations and delusions associated with Parkinson’s disease psychosis.
As of 10:42 am, the shares were trading 1.18 percent lower at ₹701.30.
